Form: 8-K

Current report filing

April 26, 2016

Exhibit 99.1

 

LOGO

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2016

Revenue increased 7% to $453.9 million; up 9% on a constant currency basis

GAAP diluted earnings per share of $0.63; non-GAAP diluted earnings per share of $0.68

Operating cash flow of $122.1 million in the third quarter

San Diego, April 26, 2016 – ResMed Inc. (NYSE: RMD) today announced results for its quarter ended March 31, 2016. Revenue for the quarter was $453.9 million, a 7 percent increase compared with the quarter ended March 31, 2015; this is a 9 percent increase on a constant currency basis.

“We have seen sustained success with the execution of our healthcare informatics strategy driving seven consecutive quarters of device growth, since the Q1 2015 launch of our Air Solutions platform. This quarter our team delivered strong double-digit growth in the Americas region, with solid global constant currency growth of 9%. Customers have responded to the value proposition of our Air Solutions platform, including the efficiencies it brings to their businesses and its ability to help them drive even better patient outcomes through connected care,” said Mick Farrell, ResMed’s chief executive officer.

“We continue to build on our offerings across our strategy for both products and informatics solutions. This quarter we announced the close of the Inova transaction, which allows us to expand our respiratory care offerings to include portable oxygen concentrators. With the acquisition of Brightree in April, we have established ourselves as the outright leader for cloud-based end-to-end solutions in HME, home health, and hospice channels.”

Farrell continued, “This expansion into new products and informatics solutions allows ResMed to continue its global leadership as a tech-driven medical device company. We are liberating healthcare data and unlocking value by providing actionable connected care solutions for patients, physicians, providers, and payers.”

Analysis of third quarter results

In the third quarter of fiscal year 2016, revenue in the Americas was $282.2 million, a 12 percent increase over the prior year’s quarter. Revenue in combined EMEA and APAC was $171.7 million, flat compared with the quarter ended March 31, 2015; this is a 3 percent increase on a constant currency basis.

Gross margin in the third quarter was 57.3 percent; this is lower than the prior year’s quarter, mainly due to changes in product mix, average selling prices and geographic mix.

Income from operations for the quarter was $104.3 million, a 1 percent decrease compared with the quarter ended March 31, 2015. Non-GAAP income from operations for the quarter was $112.4 million, a 4 percent increase compared with the quarter ended March 31, 2015.

Selling, general and administrative expenses were $119.4 million for the third quarter of fiscal year 2016, a 3 percent increase over the quarter ended March 31, 2015; this is a 5 percent increase on a constant currency basis. SG&A expenses improved to 26.3 percent of revenue in the quarter, compared with 27.5 percent in the quarter ended March 31, 2015.


Research and development expenses were $28.1 million for the third quarter of fiscal year 2016, or 6.2 percent of revenue. R&D expenses increased by 4 percent compared with the quarter ended March 31, 2015; this is an 11 percent increase on a constant currency basis.

Amortization of acquired intangible assets was $4.6 million during the quarter. Stock-based compensation costs incurred during the quarter of $10.9 million consisted of expenses associated with employee equity grants, and the company’s employee stock purchase plan.

Net income for the quarter was $88.5 million, a 3 percent decrease compared with the quarter ended March 31, 2015. Non-GAAP net income for the quarter ended March 31, 2016 was $95.4 million, a 3 percent increase compared with the quarter ended March 31, 2015 (non-GAAP measures exclude amortization of acquired intangibles and $3.6 million in acquisition expenses associated with our acquisitions of Inova and Brightree).

GAAP diluted earnings per share for the quarter were $0.63, a 2 percent decrease compared with the quarter ended March 31, 2015. Non-GAAP diluted earnings per share for the quarter were $0.68, a 5 percent increase compared with the quarter ended March 31, 2015.

Cash flow from operations for the quarter was $122.1 million, an increase from the $90.9 million reported in the quarter ended March 31, 2015 and net income in the current quarter of $88.5 million.

Share repurchase program

As previously announced, the company has temporarily suspended its share repurchase program due to recent acquisitions. The company did not repurchase any shares during the third quarter, however the company may, at any time, elect to reinitiate the share repurchase program.

Dividend program

The ResMed board of directors today declared a quarterly dividend of $0.30 per share. The dividend will have a record date of May 19, 2016, payable on June 16, 2016. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 17, 2016 for common stock holders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May 18, 2016 through May 19, 2016 inclusive. 

Webcast details

ResMed will discuss its financial and business results and outlook on its webcast at 1:30 p.m. U.S. Pacific Standard Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investors.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2016 earnings webcast” to register and listen to the live webcast. The online archive of the broadcast will be available on ResMed’s website after the live call. In addition, a telephone replay of the conference call will be available approximately two hours after the call by dialing 855-859-2056 (U.S.) and +1 404-537-3406 (international) and entering a passcode of 72407549. The telephone replay will be available until May 9, 2016.


About ResMed

ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 1 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.

ResMed.com | Facebook | Twitter | LinkedIn

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements—including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products and the integration of acquisitions—are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

Investors:

Agnes Lee

Senior Director, Investor Relations

(858) 836-5971

investorrelations@resmed.com

News Media:

Alison Graves

Director, Global Corporate Communications

(858) 836-6789

news@resmed.com

 

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)

 

    

Three Months Ended

March 31,

    

Nine Months Ended

March 31,

 
     2016      2015      2016     2015  

Net revenue

   $ 453,879       $ 422,497       $ 1,320,066      $ 1,225,848   

Cost of sales

     193,999         171,066         557,460        473,882   

SERVE-HF accrual release(1)

     —           —           (2,402     —     
  

 

 

    

 

 

    

 

 

   

 

 

 

Gross profit

     259,880         251,431         765,008        751,966   
  

 

 

    

 

 

    

 

 

   

 

 

 

Operating expenses:

          

Selling, general and administrative

     119,351         116,336         348,664        349,377   

Research and development

     28,109         27,024         84,271        86,342   

Restructuring expenses(1)

     —           —           6,914        —     

Acquisition expenses(1)

     3,550         —           3,550        —     

Amortization of acquired intangible assets(1)

     4,558         2,203         11,294        6,558   
  

 

 

    

 

 

    

 

 

   

 

 

 

Total operating expenses

     155,568         145,563         454,693        442,277   
  

 

 

    

 

 

    

 

 

   

 

 

 

Income from operations(1)

     104,312         105,868         310,315        309,689   
  

 

 

    

 

 

    

 

 

   

 

 

 

Other income (expenses), net:

          

Interest income (expense), net

     2,131         4,761         8,028        15,765   

Other, net

     2,553         3,729         3,791        6,346   
  

 

 

    

 

 

    

 

 

   

 

 

 

Total other income (expenses), net

     4,684         8,490         11,819        22,111   
  

 

 

    

 

 

    

 

 

   

 

 

 

Income before income taxes

     108,996         114,358         322,134        331,800   

Income taxes

     20,538         23,375         62,757        66,376   
  

 

 

    

 

 

    

 

 

   

 

 

 

Net income(1)

   $ 88,458       $ 90,983       $ 259,377      $ 265,424   
  

 

 

    

 

 

    

 

 

   

 

 

 

Basic earnings per share

   $ 0.63       $ 0.65       $ 1.85      $ 1.89   

Diluted earnings per share

   $ 0.63       $ 0.64       $ 1.83      $ 1.86   

Non-GAAP diluted earnings per share(1)

   $ 0.68       $ 0.65       $ 1.95      $ 1.90   

Basic shares outstanding

     140,187         140,792         140,140        140,341   

Diluted shares outstanding

     141,040         142,813         141,399        142,614   

 

(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

 

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited - In thousands)

 

     March 31     June 30,  
     2016     2015  

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 718,495      $ 717,249   

Accounts receivable, net

     358,171        362,568   

Inventories

     232,930        246,859   

Prepayments and other current assets

     90,498        81,168   
  

 

 

   

 

 

 

Total current assets

     1,400,094        1,407,844   
  

 

 

   

 

 

 

Property, plant and equipment, net

     386,771        387,758   

Goodwill and other intangible assets, net

     572,900        311,403   

Deferred income taxes and other non-current assets

     84,845        74,769   
  

 

 

   

 

 

 

Total non-current assets

     1,044,516        773,930   
  

 

 

   

 

 

 

Total assets

   $ 2,444,610      $ 2,181,774   
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

    

Current liabilities:

    

Accounts payable

   $ 77,642      $ 81,112   

Accrued expenses

     152,403        132,976   

Deferred revenue

     38,481        36,097   

Income taxes payable

     17,982        16,278   
  

 

 

   

 

 

 

Total current liabilities

     286,508        266,463   
  

 

 

   

 

 

 

Non-current liabilities:

    

Deferred income taxes

     8,297        6,372   

Deferred revenue

     36,509        19,284   

Income taxes payable

     1,754        1,754   

Other long term liabilities

     2,522        —     

Long-term debt

     435,609        300,594   
  

 

 

   

 

 

 

Total non-current liabilities

     484,691        328,004   
  

 

 

   

 

 

 

Total liabilities

     771,199        594,467   
  

 

 

   

 

 

 

STOCKHOLDERS’ EQUITY:

    

Common stock

     561        562   

Additional paid-in capital

     1,290,929        1,228,795   

Retained earnings

     2,109,371        1,976,020   

Treasury stock

     (1,546,611     (1,444,554

Accumulated other comprehensive income

     (180,839     (173,516
  

 

 

   

 

 

 

Total stockholders’ equity

   $ 1,673,411      $ 1,587,307   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 2,444,610      $ 2,181,774   
  

 

 

   

 

 

 

 

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited - In thousands)

 

    

Nine Months Ended

March 31,

 
     2016     2015  

Cash flows from operating activities:

    

Net income

   $ 259,377      $ 265,424   

Adjustment to reconcile net income to net cash provided by operating activities:

    

Depreciation and amortization

     59,827        55,310   

Impairment of long-lived asset

     2,815        —     

Gain on disposal of business

     —          (709

Stock-based compensation costs

     34,779        34,802   

Excess tax benefit from stock-based compensation arrangements

     (13,312     (20,738

Impairment of cost method investment

     750        —     

Changes in operating assets and liabilities, net of effect of acquisitions:

    

Accounts receivable, net

     2,798        (14,814

Inventories, net

     26,012        (80,793

Prepaid expenses, net deferred income taxes and other current assets

     99        (3,487

Accounts payable, accrued expenses and other liabilities

     18,516        48,484   
  

 

 

   

 

 

 

Net cash provided by operating activities

     391,661        283,479   
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Purchases of property, plant and equipment

     (44,133     (50,266

Patent registration costs

     (6,891     (7,109

Business acquisitions, net of cash acquired

     (242,645     (26,956

Investments in cost-method investments

     (8,215     (10,500

Proceeds from sale of business

     —          468   

Payments on maturity of foreign currency contracts

     (5,711     (25,232
  

 

 

   

 

 

 

Net cash used in investing activities

     (307,595     (119,595
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Proceeds from issuance of common stock, net

     16,937        23,176   

Excess tax benefit from stock-based compensation arrangements

     13,312        20,738   

Purchases of treasury stock

     (102,058     (103,295

Payment of business combination contingent consideration

     (1,228     (458

Proceeds from borrowings, net of borrowing costs

     310,000        160,000   

Repayment of borrowings

     (193,092     (1,527

Dividends paid

     (126,026     (117,862
  

 

 

   

 

 

 

Net cash (used in) / provided by financing activities

     (82,155     (19,228
  

 

 

   

 

 

 

Effect of exchange rate changes on cash

     (665     (184,061
  

 

 

   

 

 

 

Net increase / (decrease) in cash and cash equivalents

     1,246        (39,405

Cash and cash equivalents at beginning of period

     717,249        905,730   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 718,495      $ 866,325   
  

 

 

   

 

 

 

 

- More -


Reconciliation of Non-GAAP Financial Measures (Unaudited)

(In US$ thousands, except share and per share data)

The measure, “non-GAAP income from operations” is reconciled with GAAP income from operations below:

 

    

Three Months Ended

March 31,

    

Nine Months Ended

March 31,

 
     2016      2015      2016      2015  

GAAP income from operations

   $ 104,312       $ 105,868       $ 310,315       $ 309,689   

SERVE-HF accrual release (A)

     —           —           (2,402      —     

Restructuring expenses (A)

     —           —           6,914         —     

Acquisition expenses (A)

     3,550         —           3,550         —     

Amortization of acquired intangible assets (A)

     4,558         2,203         11,294         6,558   
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP income from operations (excluding the impact of SERVE-HF accrual release, restructuring expenses, acquisition expenses and amortization of acquired intangible assets)

   $ 112,420       $ 108,071       $ 329,671       $ 316,247   
  

 

 

    

 

 

    

 

 

    

 

 

 

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

 

    

Three Months Ended

March 31,

    

Nine Months Ended

March 31,

 
     2016      2015      2016      2015  

GAAP net income

   $ 88,458       $ 90,983       $ 259,377       $ 265,424   

SERVE-HF accrual release, net of tax (A)

     —           —           (1,682      —     

Restructuring expenses, net of tax (A)

     —           —           5,204         —     

Acquisition expenses, net of tax (A)

     3,550         —           3,550         —     

Amortization of acquired intangible assets, net of tax (A)

     3,416         1,643         8,572         4,951   
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP net income (A)

   $ 95,424       $ 92,626       $ 275,021       $ 270,375   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted shares outstanding

     141,040         142,813         141,399         142,614   
  

 

 

    

 

 

    

 

 

    

 

 

 

GAAP diluted earnings per share

   $ 0.63       $ 0.64       $ 1.83       $ 1.86   
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP diluted earnings per share (A)

   $ 0.68       $ 0.65       $ 1.95       $ 1.90   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(A)  ResMed excludes the impact of release of SERVE-HF accrual, restructuring expenses, acquisition-related expenses and amortization of acquired intangible assets from their evaluation of ongoing operations and believes investors benefit from excluding these charges to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share, which exclude the impact of the SERVE-HF accrual release, restructuring expenses, acquisition-related expenses and amortization of acquired intangible assets, is an additional measure of performance investors can use to compare operating results between reporting periods.

ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight in evaluating ResMed’s performance from core operations and provides consistent financial reporting. Our use of non-GAAP measures is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

- End -